Financial Performance - Q2 FY27

Revenue: INR 496.8 Cr, up 15.8% YoY from INR 429.2 Cr in Q2FY26

EBITDA: INR 134.9 Cr, up 23.9% YoY from INR 108.9 Cr in Q2FY26

EBITDA Margin: 27.2%, expanded by 180 bps from 25.4% in Q2FY26

PAT: INR 75.5 Cr, up 42.7% YoY from INR 52.9 Cr in Q2FY26

PAT Margin: 15.2%, expanded by 290 bps from 12.3% in Q2FY26

Depreciation: INR 33.0 Cr (INR 32.4 Cr in Q2FY26)

Other Income: INR 8.5 Cr (INR 0.9 Cr in Q2FY26)

Finance Cost: INR 7.9 Cr (INR 6.4 Cr in Q2FY26)

Current Tax: INR 27.0 Cr (INR 18.1 Cr in Q2FY26)

Financial Performance - H1 FY27

Revenue: INR 947.0 Cr, up 16.2% YoY from INR 815.3 Cr in H1FY26

EBITDA: INR 248.2 Cr, up 25.3% YoY from INR 198.0 Cr in H1FY26

EBITDA Margin: 26.2%, expanded by 190 bps from 24.3% in H1FY26

PAT: INR 132.4 Cr, up 34.9% YoY from INR 98.1 Cr in H1FY26

PAT Margin: 14.0%, expanded by 200 bps from 12.0% in H1FY26

Depreciation: INR 65.5 Cr (INR 63.3 Cr in H1FY26)

Other Income: INR 13.6 Cr (INR 8.4 Cr in H1FY26)

Finance Cost: INR 16.1 Cr (INR 10.9 Cr in H1FY26)

Current Tax: INR 47.8 Cr (INR 34.1 Cr in H1FY26)

Operational Metrics - Q2 FY27

B2C Revenue: INR 289 Cr, up 17% YoY

B2B Revenue: INR 208 Cr, up 15% YoY

Channel Mix: B2C 58%, B2B 42%

Patient Volume: 4.07 Mn, up 10% YoY

Test Volume: 8.68 Mn, up 11% YoY

Revenue Per Patient: INR 1,221, up 6% YoY (with no price increase)

Revenue Per Test: INR 572, up 5% YoY

Segment Performance - Q2 FY27

TruHealth Growth: 20% YoY, contributing 17% of revenue

Specialty Growth: 20% YoY, contributing 40% of revenue

Geographic Distribution - Q2 FY27

By City Tier: Tier I 66%, Tier II 8%, Tier III 26%

Infrastructure Expansion

750 service points added in Q2FY27

Balance Sheet Position (as of September 30, 2026)

Total Assets: INR 2,340.8 Cr (INR 2,138.1 Cr as of March 31, 2026)

Equity: INR 1,653.3 Cr (INR 1,524.6 Cr as of March 31, 2026)

Non-current Liabilities: INR 316.1 Cr (INR 279.5 Cr as of March 31, 2026)

Current Liabilities: INR 371.4 Cr (INR 334.0 Cr as of March 31, 2026)

Property, Plant and Equipment: INR 222.0 Cr (INR 215.3 Cr as of March 31, 2026)

ROU Assets: INR 230.2 Cr (INR 194.7 Cr as of March 31, 2026)

Goodwill: INR 660.3 Cr (INR 660.2 Cr as of March 31, 2026)

Other Intangible Assets: INR 524.0 Cr (INR 530.8 Cr as of March 31, 2026)

Investments (Current): INR 269.4 Cr (INR 140.6 Cr as of March 31, 2026)

Trade Receivables: INR 184.2 Cr (INR 170.3 Cr as of March 31, 2026)

Cash and Cash Equivalents: INR 68.7 Cr (INR 54.8 Cr as of March 31, 2026)

Strategic Initiatives - Metropolis 3.0

Key Pillars:

1. Leading with Technology - AI and digital innovation

2. Differentiate Scientifically - Scientific excellence and diagnostic quality

3. Consistent, Profitable Growth - Sustainable scaling and strategic adjacencies

4. Brand Promise - Building trust through precise, compassionate care

Technology Stack

  • Second-generation Point of Sale platform
  • Partner Portal for partner life-cycle management
  • Customer Data Platform for 360° customer view
  • Sales CRM with customizable CPQ
  • Enterprise-grade security with DPDP-compliant data handling

Scientific Expansion

  • 43 new tests added in H1FY27 (including CDP)
  • 347 tests added in FY26
  • 99% EQAS external quality assurance score
  • 99.99% report accuracy
  • 100% labs under CAP/NABL/KENAS or benchmarked
  • NGS/molecular genomics growth with AI-enabled genetic reporting
  • Centers of Excellence: Women & Child Health and Oncology

Education & Skilling

  • Metropolis Institute of Laboratory Education & Skilling (MILES)
  • UGC-certified MedTech courses with university collaboration

Medical Advisory Board

  • Internal & external i-MAB with 60 subject-matter experts

ESG Goals

Environmental: Net Zero (Scope 1 and 2) by FY43, 45% lower GHG emissions intensity by FY30, 50% renewable electricity by FY30, 50% less plastic and zero waste to landfill by FY30, 30% lower water intensity by FY30

Social: B2C NPS above 90 by FY28, 100% OHS awareness and training, 50:50 gender balance by FY28, 1 million lives impacted through CSR by FY43

Governance: Zero data breaches, patient-data protection under ISO 27001 and ISO 27701, zero instances of regulatory non-compliance

CSR Initiatives

Adolescent Reproductive Sexual Health (ARSH): 1.3 lakh+ adolescents reached, 6,300 Kishori Manch groups, 2,900 Girl Champions, 18 health facilities linked in FY27, 2.9 lakh+ Too Shy To Ask app downloads

MedEngage: 409 beneficiaries in FY26 (320 scholarships, 89 research grants), presence across 44 aspirational districts, national outreach to 12 low-reach states in FY27

Preventive Healthcare: 40,000+ preventive health screenings, TB nutrition support for 700 patients in FY27 (up from 520 in FY26), 100% treatment adherence among supported TB patients, LohaShakti anaemia programme in Palghar

Leadership Team

Ameera Shah (Promoter & Executive Chairperson), Surendran Chemmenkotil (Managing Director), Dr. Sushil Shah (Founder & Non-Executive Non-Independent Director), Sameer Patel (CFO), Avadhut Joshi (Chief Business Development Officer), Diya Suri (Chief People Officer), Dr. Kirti Kazi (Chief Scientific & Innovation Officer), Mohan Menon (Chief Marketing Officer), Bhoopendra Rajawat (Chief Business Officer West and East), Kannan Alangadan (Chief Business Officer South), Pinakin Shah (Chief Information Officer), Glen Menezes (Group Head - Customer Success), Umesh Rai (Head - Emerging Business), Ravikumar Kartha (Group Head - Internal Assurance and Business Excellence), Dr. Monika Prabhakar (Group Head - Lab Operations)

Recent Awards & Recognition (2025-2026)

  • Ameera Shah - Most Powerful Women in Business by Business Today (2026)
  • Surendran Chemmenkotil - India's Impactful Healthcare Leaders by ET Edge (2026)
  • National Winner - Diagnostics Chain of the Year by ET Healthworld (2026)
  • Excellence in Precision Diagnostics and Personalized Healthcare by ET Healthworld (2026)
  • Gold, Best Social Impact in Healthcare by FE Healthcare Excellence Awards (2026)
  • Excellence in Molecular Diagnostics by BW HealthcareWorld (2026)
  • Best Overseas Diagnostics & Laboratory Network by SEPC (2026)
  • Excellence in Women's Health Diagnostics by BW HealthcareWorld (2026)
  • Hurun India's Family Business Excellence Award to Dr Sushil Shah and Ameera Shah (2025)